Medtronic to buy Scientia Vascular in $550 million deal

By Sahil Pandey

March 10 (Reuters) – Medical device maker Medtronic said on Tuesday it would buy U.S.-based Scientia Vascular in a deal valued at $550 million, expanding its line-up of products used in stroke care.

Shares of the company were down more than 1% in early trading.

Here are some details:

* Scientia, based in Salt Lake City with about 310employees, makes guidewires and catheters used to navigate bloodvessels in the brain. * These guidewires and catheters can be seamlesslyintegrated into Medtronic’s existing suite of neurovascularproducts, the medical device maker said. * The deal positions Medtronic with a full suite of productsand supports procedures across both hemorrhagic and acuteischemic stroke, said Linnea Burman, senior vice president andpresident of Medtronic’s Neurovascular business. * Medtronic expects the deal to close in the first half offiscal 2027. * Analysts at Leerink Partners said the deal supportsMedtronic’s broader plan to lift growth through acquisitions andreflects confidence in Scientia’s underlying technology. * Evercore ISI said the acquisition is a well‑fittingtuck‑in that strengthens Medtronic’s stroke portfolio and alignswith its existing neurovascular devices. * The company also expects the deal to be minimally dilutiveto its adjusted earnings in 2027 and accretive thereafter. * Medtronic added that there could be potential earn-out andmilestone payments post-acquisition, but did not disclose anyfurther details on the same.

(Reporting by Sahil Pandey in Bengaluru; Editing by Jonathan Ananda)